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Many of the uncertainties that physicians were faced with 
regarding thromboembolic r sk in chronic atrial fibrillation 5 
years ago have been eliminated by a recent series of multi- 
center trials demonstrating the benefits of anticoagulation (1). 
However, inevitably in clinical cardiology as one solves a 
prominent part of the puzzle, new areas of uncertainty spring 
forth into puzzling prominence. In the area of thrombo- 
embolism associated with atrial fibrillation, including appro- 
priate treatment of the elderly, several key questions remain, 
such as when to use aspirin versus warfarin, the role of low 
dose warfarin and how to approach anticoagulation i the 
patient undergoing cardioversion for atrial fibrillation. 
The problem. The risk of stroke or arterial embolism due 
to clots forming in the thrombogenic milieu of the fibrillating 
atrium and subsequently being dislodged at the time of return 
of atrial mechanic function was recognized in ,early reviews of 
chemical cardioversion (2). With the development of direct 
current cardioversion this risk became even more widely 
recognized. Warfarin usage to reduce this risk became stan- 
dard practice. In 1968, Bjerkelund and Orning (3) reported on 
437 Norwegian patients admitted for electrical cardioversion 
of atrial dysrhythmias (372 with chronic atrial fibrillation). In 
that nonrandomized study approximately half of the patients 
were receiving warfarin anticoagulation a d half not, at their 
physician's discretion. The rate of embolic events (all systemic 
arterial emboli) was significantly higher in the group without 
(-5.3%) than that with anticoagulation (-0.8%). The strik- 
ingly lower event rate was even more remarkable given the 
finding that the group with anticoagulation had baseline car- 
diac characteristics (heart failure, cardiomegaly, rheumatic 
valvular disease) that put them at higher risk for thrombus. 
That study, despite its nonrandomized, nonstandardized de- 
sign served as the primary, basis for the Amerman College of 
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Chest Physicians Consensus Committee on Antithrombotic 
Therapy Recommendations (4) for the use of anticoagulation 
in the pericardioversion period. These recommendations state 
that all patients with atrial fibrillation >2 days in duration 
should receive warfarin therapy for 3 weeks before and 4 weeks 
after cardioversion until sinus rhythm has been maintained. 
There are several practical clinical problems with these recom- 
mendations, including bleeding complications related to war- 
farin, the requirement for a second hospital admission for 
cardioversion and the delay in reversion of atrial fibrillation to 
sinus rhythm. 
The solution. Because echocardiography demonstrates 
most cardiac masses with good sensitivity it was natural to try 
to utilize echocardiographic screening before cardioversion to 
look for left atrial thrombus. However, transthoracic e hocar- 
diography has a low sensitivity for left atrial thrombus because 
of the small size of the thrombi and their location in the left 
atrial appendage and thus proved to be of little use in cardiover- 
sion screening. By contrast, early studies demonstrated that 
transesophageal chocardiography (5) had an extremely high 
sensitivity and specificity for left atrial thrombus. 
As a result of these observations, we and several other 
investigators began using transesophageal chocardiography in 
1990 to screen patients who were candidates for cardioversion 
of atrial fibrillation (6-10). The concept was simple: If throm- 
boembolic events after cardioversion of atrial fibrillation are 
due to dislodgment of preexisting left atrial thrombus, and no 
thrombus can be identified before cardioversion, then antico- 
agulation can be shortened or eliminated. In our experience, 
these initial studies were performed inpatients for a variety of 
reasons, including 1) contraindication to anticoagulation; 2)
need to shorten the anticoagulation course; 3) inadequate 
duration or extent of anticoagulation; or 4) poor documenta- 
tion of anticoagulation status. 
Several studies (6-10) have established the feasibility and 
safety of this approach. Over 200 patients were examined by 
transesophageal echocardiography before cardioversion, 
thrombus was excluded, and cardioversion was performed 
without a subsequent embolic event. These observations led to 
enthusiasm for more widespread utilization of the technique. 
However, several cautionary notes were quickly sounded. 
Transesophageal chocardiographic studies by Grimm et el. 
(11) and Fatkin et al. (12) of patients undergoing electrical 
cardioversion demonstrated worsened atrial function and in 
many cases the development or worsening of atrial smoke, a 
marker for thromboembolic r sk. This raised the possibility 
that left atrial appendage thrombi may develop after electrical 
cardiovcrsion i  the milieu of a "stunned" atrium and subse- 
quently embolize. These observations, inconjunction with case 
reports (13) of patients without anticoagulation who had 
embolic events after cardioversion even with negative trans- 
esophageal echocardiographic findings, made it clear that 
some degree of anticoagulation in the pericardioversion period 
would be necessary to eliminate mbolization. 
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The present study. In this issue of the Journal, Manning et 
al. (14) report heir findings utilizing transesophageal chocar- 
diography to facilitate cardioversion of atrial fibrillation in 230 
hospitalized patients. Their study includes the 94 patients from 
their earlier report (9). Patients were selected for the trans- 
esophageal echocardiographic approach if they had atrial 
fibrillation >2 days in duration or of unknown duration. All 
but 22 had anticoagulation with intravenous heparin/warfarin. 
Thrombi were detected by transesophageal chocardiography 
in 15% of those screened, and cardioversion was deferred. Of 
the remaining 186 patients, chemical cardioversion was suc- 
cessful in 54% and electrical cardioversion in 46%. After 
successful cardioversion, all patients were treated with warfa- 
rin for 4 weeks, and no thromboembolic events were reported 
at 3 to 4 weeks of follow-up. 
The additional patients in the Manning et al. (14) study add 
to the body of evidence that transesophageal echocardio- 
graphic screening before cardioversion of atrial fibrillation is a 
safe and effective alternative to standard anticoagulant therapy 
for 3 weeks. Manning et al. appropriately emphasize several 
key features of this approach: 1) the need for therapeutic 
heparinization followed by warfarin anticoagulation i the 
pericardioversion period. Although 22 patients with physician- 
perceived contraindications to heparin safely underwent car- 
dioversion, this approach cannot be recommended routinely. 
2) Exclusion of patients receiving long-term (>3 weeks) anti- 
coagulation. The low risk of embolic events in these patients 
makes transesophageal echocardiographic s reening cost- 
ineffective. 3) Utilization of multiplane transesophageal cho- 
cardiographic probes by experienced operators. Although 50 
patients were screened by single-plane probes, we believe that 
biplane and multiplane probes allow much greater confidence 
in detecting smaller atrial appendage thrombi and that 110 ° to 
130 °planes obtainable by multiplane probes in particular aid in 
discriminating between pectinate muscles and thrombus. In 
addition, this approach can only be recommended when the 
transesophageal chocardiographic probe is in the hands of a 
very skilled and experienced operator who has performed 
>100 transesophageal chocardiographic studies. 
However, as can be expected, there are still many uncer- 
tainties regarding anticoagulation i the pericardioversion 
period: 
1) How long should warfarin therapy be continued? Manning 
et al. (14) continued warfarin therapy for 3 (according to their 
algorithm) or 4 weeks (according to their text) after cardiover- 
sion on the basis of their previous observations that atrial 
function may not return to normal for as long as 4 weeks. 
However, it is possible that return of, for example, 25% of 
atrial function seen at 24 h after cardioversion is adequate to 
prevent hrombus formation and thus eliminate the need for 
posthospital warfarin therapy altogether. 
2) Is # a cost-effective approach? Although on the surface the 
transesophageal chocardiography-guided approach would ap- 
pear to be more efficient and cost-effective, this is not neces- 
sarily the case. For example, one relatively hidden cost to the 
transesophageal chocardiography-guided approach to cardio- 
version is the discovery of previously undiagnosed atrial 
thrombi n 10% to 20% of patients. There are two possible 
approaches to the management of these patients. The first 
would be to give anticoagulation for 3 weeks and then proceed 
to cardioversion with the assumption that any residual clot has 
been safely endothelialized, minimizing its potential for dis- 
lodgment and embolization. However, we and other investiga- 
tors (6) have seen cases where 3 weeks of anticoagulation not 
only failed to eliminate or endothelialize l ft atrial clots, but 
appeared to convert hem to a higher risk appearance. 
The second approach to the thrombus would be to give the 
patient anticoagulation a d repeat he transesophageal cho- 
cardiography at an arbitrary time (3 to 6 weeks) later. How- 
ever, this adds considerable cost and delay to the transesoph- 
ageal ecbocardiography-guided approach. 
3) Is it safer or as safe as the conventional approach? 
Manning et al. (14) believe that the additional 140 patients 
included in their present study, which also includes the 94 
patients from their previously published study (9), "validate 
the safety of this strategy" and show that the approach as "a 
proved safety profile equal to conventional therapy." Unfortu- 
nately, without a randomized simultaneous comparison group 
undergoing the conventional pproach, this statement cannot 
be justified. Given the infrequency of embolic events, statistical 
power calculations indicate at least 2,800 patients are needed 
to prove comparative safety (Klein A, personal communica- 
tion, February 1995). The majority of patients in the present 
study underwent chemical cardioversion, which may have a less 
"stunning" effect on the atrium than electrical cardioversion. 
In addition, it is not clear how long patients received antico- 
agulation before successful chemical cardioversion. A pro- 
longed (36 to 72 h) precardioversion infusion of heparin in the 
patients undergoing chemical cardioversion may have substan- 
tially reduced their embolic risk compared with those under- 
going immediate lectrical cardioversion. 
The real solution. An ongoing prospective, randomized 
and controlled multicenter trial entitled the Assessment of 
Cardioversion Using Transesophageal Echocardiography 
(ACUTE) is currently under way to address these questions. 
The results of the pilot study in 123 patients indicated the 
safety and feasibility of this study and the transesophageal 
echocardiographic approach, and a preliminary assessment 
suggests that a transesophageal chocardiography-guided ap- 
proach may be 39% more cost-effective than conventional ther- 
apy (15). Patient enrollment in this study has been good, but 
several interesting obstacles have been encountered. At many 
centers, like our own, the transesophageal echocardiography- 
guided approach as been accepted as the preferred approach to 
the patient with new-onset atrial fibrillation, shortening the need 
for anticoagulation and eliminating readmission to the hospital. 
Thus, some physicians are unwilling to accept he prospect of 
their patient not being randomized to the transesophageal cho- 
cardiography arm. In other centers, where there is less transesoph- 
ageal echocardiographic expertise or experience with this ap- 
proach, physicians may be unwilling to submit heir patients to an 
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unproved approach. These difficulties only serve to emphasize the 
need to truly resolve the question. 
Clinical approach. Several recommendations canbe made 
regarding the use of transesophageal echocardiography to
guide cardioversion of atrial fibrillation based on the present 
study and the previous body of work in this area. We would 
strongly recommend that physicians practicing at institutions 
participating in the ACUTE trial make every effort to enroll 
patients in the study. The organized collection of data from a 
large series of patients will add greatly to our clinical knowl- 
edge as well as give great insight into the pathophysiology of 
left atrial thrombus and atrial thromboembolic disorders. For 
patients not enrolled in the ACUTE study, clinicians will have 
to choose the precardioversion approach that best suits their 
individual patient's special circumstances. 
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